Please assess the completion status of the following clinical trial:

Trial Title: Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. KRAS mutation NSCLC.~2. One measurable lesion as defined by RECIST 1.1 criteria for solid tumors.~3. Chemotherapy, immunotherapy or radiotherapy ≥ 4 weeks prior to starting the study treatment.~4. Surgery (except for tumor biopsy) or severe trauma ≤ 14 days prior to starting the study treatment.~5. ECOG performance status of 0-1.~6. Life expectancy ≥ 3 months.~7. Ability to take the medicine orally.~8. Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~1. Hypersensitivity to study drug ingredients or their analogues.~2. Prior therapy with MEK-inhibitor.~3. Receiving any other anti-cancer therapy at the same time .~4. Active central nervous system (CNS) lesion.~5. Bleeding symptoms at Grade 3 within 4 weeks prior to starting study treatment.~6. ECG QTcB≥480msec in screening, or history of congenital long QT syndrome；~7. Uncontrolled concomitant diseases or infectious diseases.~8. Retinal diseases (Retinal Vein Occlusion (RVO) or Retinal pigment epithelial detachment (RPED) , et al.).~9. History of HIV,HCV,HBV infection.~10. Interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis will be excluded.~11. Serum HCG test is positive.~12. Other conditions that increase the risk of study and influence the result.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- dose escalation of HL-085 plus Docetaxel (Type: EXPERIMENTAL): HL-085 will be administered as BID with specified dose. And Docetaxel will be taken as the instruction in the label ( 75mg/m2，IV).~f no Dose-limiting toxicity (DLT) occurs in the first three subjects in Cycle 1, the dose will be escalated to the next dose level; If a DLT occurs in one of the first three subjects, three additional subjects will be enrolled for the same dose cohort, and undergo the same procedures. Dose -escalation is performed based on the scheduled dose groups until DLT occurs in two or more subjects in a dose group which consists of 3 or 6 subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).